603676 Xizang Weixinkang Pharmaceutical
- 9.41
- -0.31-3.19%
Xizang Weixinkang Pharmaceutical News
Wei Xinkang (603676) In-depth Research Report: Leading Management and Development Cycle of Domestic Parenteral Nutrition
Wei Xinkang (603676) Company Brief Review Report: The impact of collection is gradually digesting performance and ushered in an inflection point
Wei Xinkang (603676): Multi-dimensional (12) steady growth awaits the release of medical insurance for new products
Wei Xinkang (603676): R&D investment continues to increase and the product matrix continues to be enriched
Wei Xinkang (603676): Performance growth was in line with market expectations, and profitability showed a month-on-month increase
Wei Xinkang (603676): New parenteral nutrition product cycle kicks off
Wei Xinkang (603676): Profit margins are gradually increasing, and new varieties are released rapidly
Wei Xinkang (603676): Core varieties maintain rapid release, new varieties continue to advance
Wei Xinkang (603676): The layout performance of all fields of parenteral nutrition continues to grow at a high rate
Wei Xinkang (603676) Company Brief Review Report: Performance Meets Expectations, Sufficient Growth Momentum in the Medium to Long Term
Wei Xinkang (603676): High performance growth in 2022 is in line with expectations and raised 2023 profit forecasts
Wei Xinkang (603676) 2022 Third Quarter Report Review: Continued Improvement in Profitability and Continued Release of Core Products Helped Performance Exceed Expectations
Wei Xinkang (603676): The accelerated growth trend in the third quarter exceeded market expectations and raised the full-year profit forecast
Wei Xinkang (603676) event comments: parenteral vitamin product matrix layout perfect channel sharing may accelerate the delivery of new products
Wei Xinkang (603676) semi-annual report 2022 comments: sustained and rapid growth of core products look forward to the further development of channels after the epidemic
Wei Xinkang (603676): the performance is located in the forecast center, and the impact of the epidemic is still high.
Wei Xinkang (603676) in-depth report: the forerunner of parenteral nutrition in the period of rapid growth
Wei Xinkang (603676) semi-annual report performance pre-increase comments: performance exceeded expectations of core products high-speed volume
Wei Xinkang (603676): focus on the high-speed release of parenteral nutrition drug core products
Wei Xinkang (603676) New Stock Research report: domestic intravenous supplements leading Enterprises
No Data
